

Supplementary Materials




Figure S1. Trend of chemotherapy status in ABI users.




Figure S2. Trend of chemotherapy status in ENZ users.




Figure S3. Trend of NHA type in post-chemotherapy patients in ENZ-era.




Figure S4. Trend of NHA type in chemotherapy-naïve patients in ENZ-era.

Table S1. Description of Novel Hormonal Agent Prescription Claims.

	Year of NHA prescription claim					
	2011	2012	2013	2014	2015	2016
Nbr of NHA claims	133	1958	4172	6767	7796	8521
Nbr of ABI claims	133	1958	3985	5756	6339	6197
Nbr of ENZ claims	0	0	187	1011	1457	2324
Prescribed daily dose (PDD) represented by claim						
ABI			ENZ			
ABI PDD 1000mg	95.2%		ENZ PPD 160mg		94.9%	
ABI PDD 750mg	1.8%		ENZ PPD 120mg		1.8%	
ABI PPD 500mg	0.8%		ENZ PPD 80mg		1.6%	
ABI PPD other	2.1%		ENZ PPD other		1.7%	